

## EMERGERS VALUE PROLIGHT DIAGNOSTICS AT 730 MSEK (0,9- 1,0 SEK PER SHARE)

In the analysis from Emergers you can e.g. read that:

- “The arrival of the first of thirty full commercial prototypes marks a pivotal moment”
- “ Prolight achieved several key technical milestones in Q3’24 as the September business review demonstrated cost-efficient, scalable cartridge production, eliminating the need for expensive liquid reagents and enabling multiplex biomarker testing from a single blood drop.”
- “Management and board members fully exercised their warrants, increasing their ownership to 22.8% of total shares—a strong signal of insider confidence in Prolight’s progress and potential.”

Read the full article here: <https://www.emergers.se/prolight-g/>

### For further information, please contact:

Ulf Bladin, CEO

E-mail: [info@prolightdx.com](mailto:info@prolightdx.com)

Phone: +46 73 582 39 87

Company website: [www.prolightdx.com](http://www.prolightdx.com)

### About Us

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

### Attachments

**EMERGERS VALUE PROLIGHT DIAGNOSTICS AT 730 MSEK (0,9- 1,0 SEK PER SHARE)**